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Abstract
The capsaicin receptor, known as transient receptor potential channel vanilloid subtype 1 (TRPV1),
is activated by a wide range of noxious stimulants and putative ligands such as capsaicin, heat, pH,
anandamide, and phosphorylation by protein kinase C (PKC). However, the identity of endogenous
activators for TRPV1 under physiological condition is still debated. Here, we report that
diacylglycerol (DAG) directly activates TRPV1 channel in a membrane-delimited manner in rat
dorsal root ganglion (DRG) neurons. 1-oleoyl-2-acetyl-sn-glycerol (OAG), a membrane-permeable
DAG analog, elicited intracellular Ca2+ transients, cationic currents and cobalt uptake that were
blocked by TRPV1-selective antagonists, but not by inhibitors of PKC and DAG lipase in rat DRG
neurons or HEK 293 cells heterologously expressing TRPV1. OAG induced responses were about
one fifth of capsaicin induced signals, suggesting that OAG displays partial agonism. We also found
that endogenously produced DAG can activate rat TRPV1 channels. Mutagenesis of rat TRPV1
revealed that DAG-binding site is at Y511, the same site for capsaicin binding, and
PtdIns(4,5)P2binding site may not be critical for the activation of rat TRPV1 by DAG in
heterologous system. We propose that DAG serves as an endogenous ligand for rat TRPV1, acting
as an integrator of Gq/11-coupled receptors and receptor tyrosine kinases that are linked to
phospholipase C.
Introduction
The capsaicin receptor, TRPV1 (transient receptor poten-
tial channel vanilloid subtype 1), is a molecular sensor
that detects a wide range of painful stimuli such as capsa-
icin, heat, and acid in nociceptive sensory neurons [1-4].
Since TRPV1 plays a pivotal role in thermal nociception
and inflammatory hyperalgesia [2,3] and is also widely
found in the central nervous system [5], considerable
effort has been made to identify endogenous activators for
TRPV1. The products of lipoxygenases, anandamide, and
other endocannabinoids [6-11] and even phosphoryla-
tion by protein kinase C (PKC) [12] in the absence of any
other agonists have been shown to directly activate
TRPV1. However, their roles under physiological condi-
tion are still debatable.
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Multiple chemical mediators such as bioactive peptides or
plasma proteins are generated in inflammatory sites, and
many of these mediators heightens the sensitivity of noci-
ceptive sensory neurons after binding to their respective
G-protein coupled receptors (GPCR) [13]. Indeed, many
Gαq coupled receptors such as bradykinin receptor 2,
prostaglandin receptor, protease activated receptor 2, his-
tamine receptor 1, and metabotropic glutamate receptors
(mGluR1 and mGluR5), are implicated in sensitization of
sensory neurons via TRPV1 modulation during inflamma-
tion-induced thermal hyperalgesia [8,14-18]. Diacylglyc-
erol (DAG) is at the core of GPCR signaling pathway and
has been shown to directly activate subfamilies of TRP
channels. Mammalian homologues of TRP family
(TRPC3, C6 and C7) are activated by DAG [19-21], raising
the possibility that DAG directly activates TRPV1. Thus, in
the present work, we set out to evaluate the possibility of
TRPV1 activation by DAG.
Materials and methods
Cell preparation and transient transfection
Dorsal root ganglia (DRG) were prepared as previously
described [22]. Briefly, Sprague-Dawley rat (OrientBio,
Korea) was decapitated, and DRG were rapidly removed
under aseptic conditions, placed in HBSS (Gibco). DRG
were digested in 0.1% collagenase and 1% collagenase/
dispase (Boehringer Mammheim) in HBSS for 10 min
respectively, followed by 10 min in 0.25% trypsin
(Sigma), all at 37°C. DRG were washed in DMEM
(Gibco) 3 times and resuspended in F 12 with 10% FBS
(Gibco) and 1% penicillin/streptomycin (Sigma). DRG
were then mechanically dissociated with fire-polished
glass pipettes, centrifuged, resuspended in F12 media, and
then plated on polyornithine (Sigma) and laminin
(Sigma)-coated glass coverslips. The cells were main-
tained at 37°C in 5% CO2 incubator. Human embryonic
kidney (HEK) 293 cells (American Type Culture Collec-
tion, Manassas, VA) were maintained according to the
supplier's recommendations. For transient transfection,
cells were seeded in 12-well plates. The next day, 0.5–2
μg/well of pcDNA constructs of TRPV1 or mutants of
TRPV1 were transfected into cells using lipofectamine
2000 transfection reagent (Invitrogen) according to the
manufacturer's protocol. After 18–24 h, cells were
trypsinized and used for whole cell recordings and Cal-
cium imaging experiments.
Electrophysiology
Whole cell currents were recorded using an Axopatch
200A amplifier (Axon Instruments). Patch pipettes were
made from borosilicate glass and had resistances of 3–5
MΩ when filled with standard intracellular solutions. For
whole cell experiments, we used an external bath medium
(normal Tyrode solution) of the following composition
(in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 glucose,
and 10 N-[2-hydroxyethyl]piperazine-N'-[2-ethanesul-
fonic acid] (HEPES), with pH adjusted to 7.4 using
NaOH. Cs+-rich external solution was made by replacing
NaCl and KCl with equimolar CsCl. CaCl2 was simply
omitted from the external bath medium to produce Ca2+-
free PSS. The pipette solution contained (in mM) 140
CsCl, 10 HEPES, 5 EGTA, and 3 MgATP, with pH adjusted
to 7.3 using CsOH. All drug solutions were applied to cells
by local perfusion through a capillary tube (1.1 mm inner
diameter) positioned near the cell of interest. The solution
flow was driven by gravity (flow rate, ~1–5 ml/min) and
controlled by miniature solenoid valves (The Lee Com-
pany, Westbrook, CT). The chamber volume was 400 μl,
and the time required to reach the chamber was ~30 s.
Latency was the time from arrival time of solution in the
chamber to the peak activation of current. Currents were
filtered at 5 kHz (-3 dB, 4-pole Bessel), digitized using a
Digidata 1322 Interface (Axon Instruments), and ana-
lyzed using a personal computer equipped with pClamp
9.0 software (Axon Instruments). The calculated junction
potential between the pipette and bath solutions used for
all cells during sealing was 4 mV (pipette negative, using
pClamp 9.0 software). No junction potential correction
was applied. Experiments were performed at room tem-
perature (18–22°C).
Ca2+ imaging
Ca2+ imaging experiment was performed as previously
described using fura-2AM (Molecular Probes, Eugene, OR,
USA) as the fluorescent Ca2+ indicator. Briefly, cells pre-
pared loaded with fura-2 AM (5 μg) mixed with 5 μl of
pluronic acid for 40 min at 37°C in a balanced salt solu-
tion [BSS; containing (in mM): 145 NaCl, 5 KCl, 2 CaCl2,
1 MgCl2, 10 HEPES, and 10 glucose] were plated onto
poly-D-lysine-coated coverslips which were mounted
onto the chamber (total volume of 500 μl), then placed
onto the inverted microscope (Olympus IX70, Japan),
and perfused continuously by BSS at a rate of 2 ml/min.
All measurements were made at 36°C as controlled by 2-
channel temperature controller PTC-20 (ALA Scientific
Instrument Inc., USA). Cells were illuminated with a
175W xenon arc lamp, and excitation wavelengths (340/
380 nm) were selected by a Lambda DG-4 monochro-
matic wavelength changer (Sutter Instrument, Novato,
CA, USA). Intracellular free Ca2+ concentration ([Ca2+]i)
was measured by digital video microfluorometry with an
intensified CCD camera (Cascade, Roper Scientific, Tren-
ton, NJ, USA) coupled to a microscope and a Pentium 5
computer with software (Metamorphor, Universal Imag-
ing Corp., PA, USA).
Cobalt uptake measurement
Our cobalt uptake staining was modified from Davis [23].
HEK 293 cells were transfected with TRPV1 and GFP and
then cultured on glass coverslips. Cells were washed 3Molecular Pain 2008, 4:42 http://www.molecularpain.com/content/4/1/42
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times with uptake buffer (in mM: Sucrose 232, NaCl 5.8,
MgCl2 2, CaCl2 0.25, Glucose 12, Hepes 10). The cells
were pretreated for 5 min with the following blockers, 100
μM 6-Iodo nor dihydrocapsaicin (6-cap), 2 μM cheleryth-
rine, 20 μM RHC 80267, and 20 μM capsazepine. Cells
were then treated for 15 min with solution containing 5
mM cobalt and various drugs. Then the cells were washed
with uptake buffer 6 times. The loaded cobalt ions were
precipitated with 0.12% Ammonium Sulfide for 5 min
and washed with uptake buffer 3 times. The cells were
immediately fixed with 4% paraformaldehyde in PBS for
10 min and then washed 3 times in PBS. To develop the
precipitated cobalt, cells were incubated with 2% sodium
tungstate in uptake buffer for 10 min. During this time,
0.25% ascorbic acid was prepared freshly and mixed with
silver nitrate solution. The mixture solution was exposed
to the cells to develop the cobalt precipitate as a dark
staining. Cells were finally washed and mounted for pho-
tography.
Whole tissue reverse transcription-polymerase chain 
reaction (RT-PCR)
Total RNA was prepared from HEK 293 cells and DRG
neurons with the use of Trizol reagent (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer's
instructions. cDNA was synthesized with the Super-
scriptTM Preamplification System (Invitrogen), as previ-
ously described [22]. PCR reaction was performed with 2
μl of the resulting cDNA, with the use of Taq DNA
polymerase (Invitrogen), and primers for PCR were 'outer'
primer.
Single-cell reverse transcription-polymerase chain reaction 
(RT-PCR)
We adopted methods described by Silbert et al. [24].
Briefly, following Ca2+ imaging experiments, we harvested
cells using patch pipettes (tip diameter, 30 μm) filled with
autoclaved distilled water under visual control and then
the cell was gently put into a reaction tube containing
reverse transcription agents. Optionally, to avoid genomic
DNA contaminations, a DNase I (for 40 min at 37°C)
digest was performed before reverse transcription. After
heat inactivation, RT was carried out for 50 min at 50°C
(superscript III, Invitrogen RT). Subsequently, the cDNA
was divided into four or five 2 μl aliquots that were used
in separate PCRs. All PCR amplifications were performed
with nested primers. The first round of PCR was pre-
formed in 50 μl of PCR buffer containing 0.2 mM dNTPs,
0.2 μM 'outer' primers, 5 μl of RT product, and 0.2 μl of
platinum Taq DNA polymerase (Invitrogen). The proto-
col included 5 min of initial denaturation at 95°C, fol-
lowed by 35 cycles of 40 s of denaturation at 95°C, 40 s
of annealing at 55°C, 40 s of elongation at 72°C, and was
completed with 7 min of final elongation. For the second
round of amplification, the reaction buffer (20 μl) con-
tained 0.2 mM dNTPs, 0.2 μM 'inner' primers, 5 μl of the
products from the first round, and 0.1 μl of platinum Taq
DNA polymerase. The reaction was the same as the first
round. The PCR products were then analyzed on an ethid-
ium bromide-stained 2% agarose gel, and photographed
using a digital camera.
Site-directed Mutagenesis
Point mutant Y511A of TRPV1 was produced with a two
step PCR approach from TRPV1 construct which was gen-
erated in our lab. In brief, it was generated by a combina-
tion of two overlapping PCR fragments, which were
constructed from complimentary mutagenic primers. The
following primers contained the single point mutation
shown in bold (5'-GAGGAGTCGCCTTCTTCTTCC and 5'-
GGAAGAAGAAGGCGACTCCTC). TRPV1 mutant of
Δ747–838 was produced by one-step PCR-based method.
Briefly, the PCR product containing SacII/KpnI sites was
obtained with an internal forward primer (CGCTTACAG-
CAGCAGTGAGACCC) and a KpnI site-stop codon-tailing
reverse primer (TATGGTACCTTACAGGGTGCGCTT-
GACGCCCTC). The pcDNA3.1 (+)/TPRV1 construct
digested with SacII/KpnI was ligated with the PCR prod-
uct. After mutagenesis, the sequences of the final con-
structs were confirmed by DNA sequencing.
Statistics
Results are expressed as mean ± SE. Where appropriate,
results were compared using 2-tailed Student's t-test
(paired or non-paired) or ANOVA test.
Results
OAG induces Ca2+ influx in DRG neurons
We first examined whether 1-oleoyl-2-acetyl-sn-glycerol
(OAG), a DAG analog, can induce Ca2+ responses in rat
DRG neurons. We performed fura-2 ratiometric Ca2+
imaging experiments to verify TRPV1 activation by 100
μM OAG. An increase in [Ca2+]i was elicited by 100 μM
OAG in capsaicin-responsive DRG neurons (Figure 1a),
which was abolished by a pretreatment with the TRPV1
blocker, 10 μM capsazepine (Figure 1b) and with 0 mM
Ca2+ in the bath solution (Figure 1c), indicating that Ca2+
transients induced by 100 μM OAG is mostly due to the
influx of Ca2+ through TRPV1 rather than the mobiliza-
tion from intracellular Ca2+ stores. Of the 44 DRG neu-
rons that showed a response to capsaicin we found that 31
neurons responded. 13 out of 44 neurons only showed
capsaicin response. Less than 5% of the DRG neurons
responded only to OAG and these cells possibly represent
an OAG activation of other TRPC channels. The summary
of peak amplitude showed that OAG-induced Ca2+ tran-
sients were about 23% of capsaicin-induced Ca2+ tran-
sients, and almost were completely inhibited by
capsazepine (Figure 1d). Additionally, concentration-
response curve of OAG-induced Ca2+ transient showedMolecular Pain 2008, 4:42 http://www.molecularpain.com/content/4/1/42
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that the half-maximal concentration (EC50) of OAG is
42.8 μM (Figure 1e).
OAG-induced Ca2+ transients correlate RNA expression of 
TRPV1 in each DRG neuron
To determine whether OAG-induced Ca2+ transients are
mediated by TRPV1 or by other TRPC members in the TRP
family, we performed RT-PCR on whole DRG tissue and
OAG induces Ca2+ influx in rat DRG neurons that is blocked by capsazepine (CZP) Figure 1
OAG induces Ca2+ influx in rat DRG neurons that is blocked by capsazepine (CZP). (a) The representative trace of 
fura-2 ratiometric Ca2+ imaging reveal activation of TRPV1 by 100 μM OAG in capsaicin (CAP) responsive DRG neurons. Ca2+ 
transients were evoked by the application of 100 μM OAG, (b) whereas Ca2+ transients were blocked by the pretreatment of 
10 μM CZP and (c) of 0 mM Ca2+ in the extracellular solution. The DRG neurons were exposed to 1 μM capsaicin to deter-
mine capsaicin-sensitivity in the end of each experiment. (d) Summary of Ca2+ transient responses to 1 μM capsaicin, 100 μM 
OAG, 100 μM OAG with 10 μM CZP, as measured by peak amplitude of ratio for each transient. The mean value of OAG-
induced Ca2+ transient was 0.086 ± 0.012, while that of capsaicin-induced Ca2+ transient was 0.36 ± 0.032. The OAG-induced 
Ca2+ transient was blocked by 10 μM CZP (0.001 ± 0.003). Each p value was indicated on each bar group. (e) The concentra-
tion-response curve of OAG response in DRG neurons obtained from ratiometric Ca2+ imaging.
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individual DRG neurons harvested after testing with 100
μM OAG and 1 μM capsaicin. The results of RT-PCR on
the whole DRG tissue showed that the various subtypes of
TRP family which are Ca2+-permeable channels were
detected (Figure 2b). In order to determine the correlation
between Ca2+ influx and subtypes of TRP family, single-
cell RT-PCR technique was employed. All of DRG neurons
responsive to both 100 μM OAG and 1 μM capsaicin
expressed TRPV1 mRNA (Figure 2c, n = 6/6), whereas all
of DRG neurons unresponsive to both 100 μM OAG and
1 μM capsaicin did not (Figure 2c, n = 4/4). Most cells
(Figure 2c, n = 9/10) expressed TRPC6 and some of them
responded to 100 μM OAG (Figure 2c, n = 4/9). These
results indicated that there was a strong correlation
between TRPV1 mRNA expression and OAG-responsive-
ness. In addition none of these cells expressed TRPC3 or
TRPC7 (Figure 2c), even though both TRPC3 and TRPC7
were detected in whole DRG tissue (Figure 2b). There was
a lack of correlation between an OAG-induced Ca2+ tran-
sient and TRPC6 expression in DRG neurons, since only 4
out of 9 cells expressing TRPC6 showed OAG-induced
Ca2+ transient. Taken together, these results demonstrated
that DAG-mediated Ca2+ response in DRG neurons is
strongly correlated with TRPV1 expression.
OAG-induced Ca2+ transients correlate with mRNA expression of TRPV1 in each DRG neuron Figure 2
OAG-induced Ca2+ transients correlate with mRNA expression of TRPV1 in each DRG neuron. Combination of 
single-cell RT-PCR following Ca2+ imaging (n = 10) revealed an association between expression of TRPV1 and the responsive-
ness to both OAG and capsaicin. DRG neurons responsive to 100 μM OAG and 1 μM capsaicin (Number 1 and 2 on (a), n = 
6/10) expressed TRPV1 (n = 6/6), whereas DRG neurons unresponsive to 100 μM OAG and 1 μM capsaicin did not (number 
3 on a, n = 4/4). Most cells (n = 9/10) expressed TRPC6 and some of them did not respond to 100 μM OAG (n = 4/9). (a) 
Three images represent fura-2 ratio images before and during 100 μM OAG and 1 μM capsaicin applications. Traces show Ca2+ 
transients in response to OAG or capsaicin application. (b) Acutely prepared DRG tissues showed the RNA expression level 
on TRP subfamilies. (c) Single cell RT-PCR results showed the mRNA level of TRP subfamilies. Numbers indicate each cell 
shown in single cell RT-PCR results.
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OAG induces Ca2+ transient and inward currents via TRPV1 
in HEK 293
To exclude the involvement of TRPC subfamily in OAG-
induced responses, we used HEK 293 cells, which do not
express TRPC3, TRPC6, and TRPC7 (Figure 3a). In agree-
ment with the Ca2+  responses observed in capsaicin-
responsive DRG neurons, Ca2+ imaging data performed in
HEK 293 cells showed that an increase in [Ca2+]i was also
induced by treatment of 100 μM OAG in TRPV1-express-
ing, capsaicin-sensitive cells (Figure 3b, upper panel), and
these responses were blocked by treatment with 10 μM
capsazepine (Figure 3b, lower panel). In addition, con-
centration-response curve of OAG-induced Ca2+ transient
in TRPV1-expressing HEK 293 cells showed that EC50 is
13 μM (Figure 3c). To test whether the intracellular store
of Ca2+ contributes to OAG-induced Ca2+ transients in
TRPV1-expressing HEK 293 cells, we blocked Ca2+ release
from internal store by treating with 1 μM thapsigargin. We
found that 1 μM thapsigargin treatment minimally
affected OAG-induced Ca2+ transient. In the presence of 1
μM thapsigargin, the peak ratio values of OAG and CAP-
induced Ca2+ transients were 0.15 ± 0.040 and 0.52 ±
0.042 (Figure 3d, e) respectively, while the peak ratio val-
ues of those in the absence of thapsigargin were 0.17 ±
0.047 and 0.86 ± 0.067 (Figure 3d, e). The percentage of
OAG response to capsaicin response was about 20%,
which was similar to that shown in DRG neuron (Figure
1d). Although the average OAG response did not change
in the presence and absence of 1 μM thapsigargin, there
was a reduction of capsaicin-induced Ca2+ transients in
the presence of thapsigargin (Figure 3e). This is probably
due the fact that capsaicin causes an increase in [Ca2+]i not
only by Ca2+ entry through TRPV1 but also by releasing
Ca2+ from intracellular stores [25].
To test whether OAG is enough to activate TRPV1, we per-
formed whole-cell patch clamp in HEK 293 cells hetero-
gously expressing TRPV1. We found that treatment of
OAG induced inward current in TRPV1-expressing HEK
293 cell, which strongly desensitized within a minute and
recovered after 5 min (Figure 4Aa). OAG-induced inward
currents were observed only in TRPV1-expressing HEK
293 cells but not in untransfected cells, and this current
was blocked by 10 μM capsazepine (Figure 4Ac). This
summary bar graph showed that OAG-induced inward
current was about 20% in capsaicin-responsive cells (Fig-
ure 4Ad) and this result suggests that OAG might act as a
partial agonist. Other analogs of DAG including 100 μM
SAG and 100 μM DOG also evoked inward currents (data
not shown), suggesting that these effects are general phe-
nomena associated with DAG analogs.
Next, we performed Co2+  uptake assay using TRPV1-
expressing HEK 293 cell since this technique has been
extensively used as a functional assay for TRPV1 channel
activity [23]. We treated 100 μM OAG and measured Co2+
uptake through TRPV1 expressed in HEK 293 cells. We
found that, like capsaicin, 100 μM OAG induced Co2+
uptake although with lower intensity and less number of
cells (Figure 4B). The Co2+ uptake by OAG and capsaicin
was blocked by TRPV1-selective antagonists, including 50
μM 6-iodonordihydrocapsaicin or 10 μM capsazepine
(Figure 4B). Taken together, our results support the idea
that OAG could activate TRPV1 and OAG-induced
responses in DRG neurons are mediated by TRPV1.
OAG-induced TRPV1 activation is PKC- and DAG-lipase 
independent
We next tried to determine the underlying mechanism of
OAG-induced TRPV1 activation. Since it has been known
that DAG analogs directly activate other members of TRP
channels, such as Drosophila TRP channels [20,21] and
mammalian TRPC channels [19,20], we tested whether
DAG analogs can induce TRPV1-meidated currents
directly via a membrane-delimited pathway, independent
of PKC or DAG-lipase. To eliminate the possible contribu-
tion of PKC phosphorylation and the activity of DAG
lipase to the OAG-induced responses, we performed
whole-cell recordings from HEK 293 cells transiently
expressing TRPV1 with a pipette solution containing
either 1 μM chelerythrine, a well known PKC inhibitor, or
10 μM RHC80267, a highly selective DAG lipase inhibitor
[26]. We found that the application of 100 μM OAG
induced TRPV1 current in the presence of 1 μM cheleryth-
rine or 10 μM RHC80267 in the pipette solution, indicat-
ing that OAG could induce TRPV1 current in PKC or DAG-
lipase independent manner (Figure 5Aa). In order to
allow complete diffusion of these inhibitors, OAG was
applied twice, at 1 min and 10 min after rupture of the cell
membrane. The amplitude of OAG-induced current was
similar when OAG applied 1 min or 10 min (Figure 5Aa,
b), indicating that PKC or DAG-lipase did not have much
role in induction of TRPV1-meidated current by OAG. We
independently tested the effective block of PKC by 1 μM
chelerythrine in a separate experiment. At this concentra-
tion, chelerythrine effectively blocked the tachyphylaxis
of TRPV1 upon repetitive stimulation [see Additional file
1], which is known to be caused by PKC phosphorylation
of TRPV1 [27]. The Co2+ uptake induced by 100 μM OAG
in TRPV1-expressing HEK 293 cells was also discernable
even in the presence of 1 μM chelerythrine and 10 μM
RHC80267 (Figure 5B), further supporting the direct acti-
vation of TRPV1 by 100 μM OAG.
Endogenously produced DAG activates TRPV1 channels in 
a heterologous expression system
DAG is produced upon activation of Gαq/11-coupled
receptors or a class of receptor tyrosine kinases, which
then activates phospholipase C, resulting in the conver-
sion of PtdIns(4,5)P2 to DAG and IP3 [19]. Thus, we exam-Molecular Pain 2008, 4:42 http://www.molecularpain.com/content/4/1/42
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Figure 3 (see legend on next page)
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ined whether endogenously produced DAG can activate
TRPV1 channels. In HEK 293 cells over-expressing M3, a
Gαq/11-coupled muscarinic acetylcholine receptor, the
addition of 30 μM acetylcholine did not induce any signif-
icant current (Figure 6a lower left panel). However, in
HEK 293 cells expressing both M3 and TRPV1, acetylcho-
line induced significant inward currents even in the pres-
ence of both 1 μM chelerythrine and 10 μM RHC80267 in
the pipette solution (Figure 6a upper left panel). The ace-
tylcholine-induced currents were almost completely
blocked by 10 μM capsazepine (Figure 6a upper right, b),
indicating that the acetylcholine-induced current is medi-
ated by TRPV1. These results provide strong support for
DAG acting as an endogenous ligand for TRPV1.
OAG binds to the capsaicin binding site
We next examined the molecular target of DAG on TRPV1
activation. One plausible mechanism of this pathway is
DAG directly interacting with TRPV1. To test this possibil-
ity we transiently expressed in HEK 293 cells with Y511A
mutant of TRPV1 which has impaired capsaicin binding
site and found that both OAG and capsaicin failed to elicit
a current response (Figure 7b), suggesting that capsaicin
and OAG share the binding site at Y511 for activation of
TRPV1. Next, we tested whether OAG induce any current
in TRPV1 mutants which lack PKC binding sites [28].
Both OAG- and capsaicin-induced currents remained
unaffected in double mutations with disrupted PKC bind-
ing sites, S502A/S800A (Figure 7b), while the double
mutations, S502A/T704I of TRPV1, which lacks the bind-
ing site of PKC and Ca2+-calmodulin dependent kinase II
(CaMKII) were unresponsive to both OAG and capsaicin.
These results with mutant analysis suggest that PKC phos-
phorylation does not play a critical role in the induction
of TRPV1 activation by 100 μM OAG, but phosphoryla-
tion by CaMKII is required for the OAG-induced activa-
tion of TRPV1 [29]. Collectively, our results obtained
from TRPV1 mutants suggest that DAG analogs open
TRPV1 by binding at Y511 just as capsaicin does and
could compete the binding at Y511 site with capsaicin. To
directly test this possibility, we applied sub-saturating
concentration of capsaicin (100 nM) to induce whole-cell
currents and switched to 100 μM OAG in the presence of
capsaicin. OAG rapidly and robustly replaced capsaicin,
and induced a small inward current (Figure 7d). Taken
together, it indicated that OAG and capsaicin share a sim-
ilar binding site. Our results consistently support the
hypothesis that DAG and its analogs activate TRPV1
directly by binding at the capsaicin-binding site. Alterna-
tively, DAG might produce its effects by displacing
PtdIns(4,5)P2  from an inhibitory site on TRPV1 [30].
Thus, we also tested whether DAG would activate TRPV1
in  Δ774–838 deletion mutant of TRPV1, which lacks
PtdIns(4,5)P2 binding site (786–828) [28]. We observed
that OAG induced inward current on HEK 293cell
expressing Δ774–838 deletion mutant of TRPV1 (Figure
7b), indicating that OAG-induced activation of TRPV1 is
independent of the inhibitory site (774–838) on TRPV1.
Discussion
Our study proposes that DAG is a novel endogenous lig-
and of TRPV1 and regulates Ca2+ signaling in rat DRG neu-
rons. It has been well demonstrated that the activation of
TRPV1, via GPCRs for bradykinin, histamine, prostaglan-
din, and serotonin, is associated with sensitization of
peripheral nociceptors during thermal and inflammatory
hyperalgesia [8,15,16,31,32]. Although lipid metabolite
products such as HPETE [7] and anandamide [11] have
been suggested as candidate molecules mediating GPCR-
activation of TRPV1, an endogenous ligand for TRPV1 in
the physiological condition is still debated. In the present
study, we found that endogenous DAG produced by
GPCR-activation directly activates TRPV1 even in the pres-
ence of PKC and DAG lipase inhibitor (Figure 6a). These
responses are readily inhibited by capsazepine, a selective
TRPV1 blocker (Figure 1b). However, the efficacy of OAG
was much less than that of capsaicin, displaying only one
fifth of capsaicin induced responses, suggesting that OAG
is acting as a partial agonist. Therefore, in addition to
TRPC3 TRPC6, and TRPC7, which are activated by DAG
[21], we demonstrate that TRPV1 is also activated by DAG
and other DAG analogues such as OAG, SAG, and DOG.
OAG-induced Ca2+ increase is inhibited by TRPV1 blockers in heterologous expression system Figure 3 (see previous page)
OAG-induced Ca2+ increase is inhibited by TRPV1 blockers in heterologous expression system. (a) RT-PCR anal-
ysis showed that in untransfected HEK 293 cells, there was no endogenous expression of TRPV1, TRPC3, TRPC6 or TRPC7. 
TRPV1 expression was detected in TRPV1-transfected HEK 293 cells. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was positive control on RT PCR. (a) Ratiometric Ca2+ imaging loaded with fura-2AM revealed activation of TRPV1 by 100 μM 
OAG. (b) OAG application evoked Ca2+ transients that were blocked by the pretreatment with 10 μM CZP. Capsaicin-induced 
Ca2+ transients confirmed expression of functional TRPV1 in the transfected HEK 293 cells. (c) Concentration-response rela-
tionship of OAG response in TRPV1-expressing HEK 293 cells obtained from ratiometric Ca2+ imaging. (d, e) The OAG-
induced Ca2+ transients persist in the presence of 1 μM Thapsigargin (Thap). (f) The summary bar graph was generated from 
the peak Ca2+ responses of OAG-induced and capsaicin-induced Ca2+ transients in the absence and presence of 1 μM thapsi-
gargin. Although the capsaicin-induced Ca2+ transient was slightly decreased, there was no difference in OAG-induced-Ca2+ 
transients between both conditions.Molecular Pain 2008, 4:42 http://www.molecularpain.com/content/4/1/42
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Figure 4 (see legend on next page)
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This result suggested that GPCR-coupled DAG could serve
as endogenous ligand of TRPV1 in central nervous system
as well as in periphery.
It was reported, using single channel studies of inside-out
patches, that TRPV1 is activated by several products of
lipoxygenase, but minimally by 1-Stearyl-2-arachinonyl-
sn-glycerol (SAG), another analog of DAG [7]. This dis-
crepancy might be due to the difference in extracellular
Ca2+ levels in the recording conditions and/or the patch
clamp recording mode employed. Another report has pro-
vided evidence against direct activation of TRPV1 by DAG
in a heterologous system utilizing the Chinese Hamster
Ovary (CHO) cell line [21]. However, other recent reports
demonstrate the complexity of lipid signaling in cell
membrane which includes cell-type specificity [33] and
different channel activities depending on the mode of
patch clamp recording [34].
Our results with whole-cell current recordings in heterol-
ogous system indicate that the binding site of DAG might
be similar to that of capsaicin. In a competition assay, we
found that OAG competitively and rapidly replaced the
bound capsaicin, causing reduced whole-cell current
amplitude (Figure 7d). These results strongly suggest that
DAG binds directly to the capsaicin binding site. In addi-
tion, both OAG and capsaicin did not induce any current
on the mutant form of TRPV1 with S502A/T704I, which
represents the PKC and CaMKII phosphorylation sites.
However, OAG and capsaicin induced inward current on
the mutant with S502A/S800A, representing the PKC
binding sites. These results suggest that like capsaicin,
phosphorylation by CaMKII is required for the OAG-acti-
vation of TRPV1. Interestingly, in Δ774–838 deletion
mutant of TRPV1, which lacks PtdIns(4,5)P2 binding site
(786–828) (Figure 7b), we observed a bigger inward cur-
rent by OAG than in wild type TRPV1 (Figure 5Aa) or
S502A/S800A mutant (Figure 7b), which is consistent
with the previous observation that PtdIns(4,5)P2 binding
site displays an inhibitory effect of TRPV1 regulation on
low concentration of capsaicin [35].
Conclusion
In summary, the current study demonstrates that DAG is
an endogenous ligand for activating TRPV1 by binding at
the capsaicin binding site but by acting independently of
PKC and lipoxygenase pathway. Our findings should
stimulate future investigations in this new pathway of
TRPV1 activation, and promise new ways to develop
novel drugs for reducing pain.
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OAG-induced inward current is inhibited by TRPV1 blockers in heterologous expression system Figure 4 (see previous page)
OAG-induced inward current is inhibited by TRPV1 blockers in heterologous expression system. (Aa) Currents 
generated by repetitive 100 μM OAG application showed recovery from desensitization. The intervals of each trace were 1 
min, 2 min, and 3 min as indicated. (Ab) The repeated application of OAG currents showed full recovery after 5 min on a dif-
ferent cell. (c, upper panel) 100 μM OAG induced inwarnd current in HEK cell expressing TRPV1 which responded to 1 μM 
capsaicin. (c, lower panel) 100 μM OAG elicited inward currents that were abolished by 10 μM CZP in TRPV1-transfected 
cells. OAG did not induce any current in untransfected cells. (d) Summary of the current responses to 1 μM capsaicin, 100 μM 
OAG, and 100 μM OAG with 10 μM CZP, as measured by peak current amplitude. The asterisk showed significant difference 
in OAG-induced Ca2+transient blocked by CZP (t-test, P < 0.05). (g) Co2+ uptake experiments further verified TRPV1 activa-
tion by 100 μM OAG. Co2+ uptake induced by 100 μM OAG (upper middle panel) was abolished by the TRPV1 antagonist, 100 
μM 6-iodonordihydrocapsaicin (6-CAP) (lower middle panel). Lower panel shows the same experimental condition for capsai-
cin.Molecular Pain 2008, 4:42 http://www.molecularpain.com/content/4/1/42
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OAG-induced TRPV1 activation is PKC and DAG-lipase independent Figure 5
OAG-induced TRPV1 activation is PKC and DAG-lipase independent. (Aa) OAG-induced current was well gener-
ated in 1 μM chelerythrine, a PKC inhibitor in the internal pipette solution in the whole cell patch mode on the condition of 1 
min (left trace) and 10 min (right trace) after rupturing cell. (Ab) OAG-induced current was also examined in 10 μM 
RHC80267, a DAG-lipase inhibitor in the same manner. (c) The summary bar graph was derived from the current peak ampli-
tude in both conditions a PKC inhibitor and a DAG-lipase inhibitor at each 1 min and 10 min recording data. Each inhibitor was 
included in the patch pipette solution. (d) Co2+ uptake by OAG in TRPV1 expressing HEK 293 cells were observed even in the 
presence of 1 μM chelerythrine and 10 μM RHC80267 and was blocked by 10 μM CZP, similar to 1 μM capsaicin.
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Endogenously produced DAG activates TRPV1 channels in a heterologous expression system Figure 6
Endogenously produced DAG activates TRPV1 channels in a heterologous expression system. (a) Activation of 
muscarinic receptor M3 by 30 μM Acetylcholine (Ach) opened TRPV1 channels (a, upper left panel) in HEK 293 cells coex-
pressing M3- and TRPV1 (upper left panel). Patch pipette solution contained both 1 μM chelerythrine and 10 μM RHC80267 
Ach-induced currents were almost completely blocked by 10 μM CZP (upper right panel). Ach-induced currents were not 
observed in HEK 293 cells expressing only M3 (lower left panel). (b) Summary of Ach-evoked currents. Asterisks represent a 
significant difference by ANOVA test followed by Tukey – Kramer multiple comparison test (n. s: non-significant, ** p < 0.001).
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OAG binds to the capsaicin binding site Figure 7
OAG binds to the capsaicin binding site. (a) An illustration of the topology of TRPV1. The capsaicin binding site and puta-
tive PKC and CaMKII phosphorylation sites were shown. (b) Like capsaicin, OAG failed to activate inward currents in Y511A 
and S502A/T704I mutants of TRPV1. In contrast, OAG-evoked currents were produced in S502A/S800A and Δ774–838 
mutants of TRPV1. (c) Summary of OAG (O) and capsaicin (C) evoked current responses in the TRPV1 mutants indicated in b. 
(d) Currents evoked by 100 nM capsaicin were partially blocked by 100 μM OAG. The remaining currents between the two 
arrows were considered to be OAG-induced currents. (e) Summary of OAG (O) and CAP (C) evoked currents. The asterisk 
showed significant difference in normalized OAG-induced current (paired t-test, p < 0.05).
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Chelerythrine, a PKC inhibitor, inhibits the tachyphylaxis of capsaicin-
induced current. The desensitized current was shown in the subsequent 1 
μM capsaicin treatment (left panel) at every 100 s. The inhibition of 
desensitization was shown in the presence of 1 μM chelerythrine of the 
internal pipette solution (middle panel). Right panel shows the summary 
of peak amplitude ratio of second and third divided by the first capsaicin-
induced current between in the presence of and in the absence 1 μM chel-
erythrine.
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